Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Paramount Bed Holdings (7817 JP): Guidance Reaffirmed, But Sluggishness To Stay Amid Falling Margins

Paramount Bed Holdings (7817 JP): In-Line Q1 Result; FY24 Guidance Reaffirmed

Paramount Bed (7817 JP): All-Time Revenue and Profit in FY23; Further Upside Potential Remains

Equity Bottom-Up

Paramount Bed Holdings Co Lt / Equity Bottom-Up

<ul>
<li>In FY25, <a href="https://www.smartkarma.com/entities/paramount-bed-holdings-co-lt" target="_blank" data-smartkarma-citation="entities:17808:1" rel="noopener">Paramount Bed Holdings Co Lt (7817 JP)</a> reported 2% YoY revenue growth to ¥109B, mainly driven by the nursing care business.</li>
<li>Due to higher SG&amp;A expenses, operating profit decreased 6% YoY to ¥13B and net profit was down 15% YoY to ¥9B.</li>
<li>Paramount guided FY26 revenue to grow 4% YoY to ¥113B and also trimmed FY27 targets in mid-term plan.</li>
</ul>


In FY25, Paramount Bed Holdings Co Lt (7817 JP) reported 2% YoY revenue growth to ¥109B, mainly driven by the nursing care business.
Due to higher SG&amp;A expenses, operating profit decreased 6% YoY to ¥13B and net profit was down 15% YoY to ¥9B.
Paramount guided FY26 revenue to grow 4% YoY to ¥113B and also trimmed FY27 targets in mid-term plan.


Paramount Bed Holdings (7817 JP): Demand to Remain Sluggish; Margins to Hold, For Now